Literature DB >> 1925633

The therapeutic use of monoclonal antibodies in colorectal carcinoma.

H Mellstedt1, J E Frödin, G Masucci, P Ragnhammar, J Fagerberg, A L Hjelm, J Shetye, P Wersäll, A Osterborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1925633

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  14 in total

Review 1.  Monoclonal antibodies in cancer therapy.

Authors:  R Gruber; E Holz; G Riethmüller
Journal:  Springer Semin Immunopathol       Date:  1996

Review 2.  Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.

Authors:  P Ragnhammar
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

3.  Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.

Authors:  A P Zbar; H Thomas; R W Wilkinson; M Wadhwa; K N Syrigos; E L Ross; P Dilger; T G Allen-Mersh; W A Kmiot; A A Epenetos; D Snary; W F Bodmer
Journal:  Int J Colorectal Dis       Date:  2005-04-30       Impact factor: 2.571

4.  Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.

Authors:  P Ragnhammar; G Masucci; J E Frödin; A L Hjelm; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  The clinical significance of HAMA in patients treated with mouse monoclonal antibodies.

Authors:  J E Frödin; A K Lefvert; H Mellstedt
Journal:  Cell Biophys       Date:  1992 Aug-Dec

6.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

7.  The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).

Authors:  P Ragnhammar; I Magnusson; G Masucci; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

8.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?

Authors:  J Fagerberg; J E Frödin; P Ragnhammar; M Steinitz; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

9.  Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.

Authors:  S B Hosch; P Scheunemann; M Lüth; S Inndorf; N H Stoecklein; A Erbersdobler; A Rehders; M Gundlach; W T Knoefel; J R Izbicki
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

Review 10.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.